Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study

INTRODUCTION: Lung cancer is the most common cause of cancer mortality in the UK, and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most patients present with inoperable disease; therefore, radiotherapy plays a major role in treatment. However, the majority o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatton, Matthew Q F, Lawless, Claire Anne, Faivre-Finn, Corinne, Landau, David, Lester, Jason F, Fenwick, John, Simões, Rita, McCartney, Elaine, Boyd, Kathleen Anne, Haswell, Tom, Shaw, Ann, Paul, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352760/
https://www.ncbi.nlm.nih.gov/pubmed/30700475
http://dx.doi.org/10.1136/bmjopen-2017-019903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352760/
https://www.ncbi.nlm.nih.gov/pubmed/30700475
http://dx.doi.org/10.1136/bmjopen-2017-019903

Ejemplares similares